BCL2L11 and cancer: In cancer cells, the combined therapy with vemurafenib and oligomycin substantially increased the expression of the ER-resident chaperone Grp78, the pro-apoptotic protein Bim and the cleaved fragment of PARP compared with vemurafenib treatment alone (Figure 2B).